Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 31;47(2):E134–E147. doi: 10.1503/jpn.210145

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 CMA Impact Inc. or its licensors

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Antipsychotic medications normalized elevated D2R-DISC1 complex levels in peripheral blood samples from patients with schizophrenia (Beijing cohort). (A) Coimmunoprecipitation shows that antipsychotic medications reduced D2R-DISC1 complex levels in peripheral blood samples from patients with schizophrenia. (B) Densitometric analysis of DISC1 coimmunoprecipitated by D2R from peripheral blood samples of patients with schizophrenia before and after antipsychotic treatment, and of unaffected controls. **p < 0.01 versus controls. ###p < 0.001 versus patients with schizophrenia before treatment. One-way analysis of variance followed by a Tukey post hoc test (n = 31 patients with schizophrenia before and after treatment; n = 12 unaffected controls). (C) Graph displaying D2R-DISC1 complex levels before and after treatment. (D) PANSS positive scale score was positively correlated with D2R-DISC1 complex levels in patients with schizophrenia before and after antipsychotic treatment (n = 31 patients with schizophrenia). (E) PANSS scores for patients with schizophrenia before and after treatment (n = 31 patients with schizophrenia before and after treatment; n = 12 unaffected controls); t test, *p < 0.05, ****p < 0.001 compared to before treatment. Co-IP = coimmunoprecipitation; D2R = dopamine 2 receptor; DISC1 = disrupted in schizophrenia 1; IB = immunoblotting; IgG = immunoglobulin G; IP = immunoprecipitation; PANSS = Positive and Negative Syndrome Scale.